Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Go back to Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
(NASDAQ: ASMB) Delayed: 24.44 --0 (-0%)
Previous Close $24.44    52 Week High $14.50 
Open $24.44    52 Week Low $4.33 
Day High $24.44    P/E N/A 
Day Low $24.44    EPS $0.00 
Volume 159